Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period
Phase of Trial: Phase III
Latest Information Update: 12 Jul 2018
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms GEMELLI 1
- Sponsors Sanofi
- 30 Jan 2018 Planned patient number has been changed to 880.
- 22 Jan 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jul 2018.
- 22 Jan 2018 Planned number of patients changed from 500 to 580.